NCT06736548 Sleep Treatment Education Program for Cancer Survivors: STEP-Together
| NCT ID | NCT06736548 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | Insomnia |
| Study Type | INTERVENTIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-06-25 |
| Primary Completion | 2026-10-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 100 participants in total. It began in 2025-06-25 with a primary completion date of 2026-10-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This single-arm research study of off-treatment cancer survivors with self-reported symptoms of insomnia will test the Sleep Treatment Education Program Together (STEP-Together) intervention which is delivered as a synchronous group session by videoconference.
Eligibility Criteria
Inclusion Criteria: * Age 18-89 * History of a cancer diagnosis (except non-melanoma skin cancer) ≥ 6 months prior * No active cancer therapy (excluding chemoprevention) in the past four months, and no further therapy planned. * Significant insomnia as evidenced by an Insomnia Severity Index score ≥ 8 * Regular access to the internet * Able to read and write in English Exclusion Criteria: * Usual bedtime does not fall between 5:00 pm and 5:00 am. * Employment in a position where falling asleep at work could impact public safety (such as air traffic-controller, operating heavy machinery). * Ever diagnosed with Bipolar Disorder or with Seizure Disorder, currently taking medications to prevent a seizure, or have experienced a seizure in the prior 12 months. * Any impairment (e.g., hearing, visual, cognitive) that interferes with the ability to complete all study procedures independently.
Contact & Investigator
Christopher Recklitis, PhD, MPH
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT06736548 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 89 Years, studying Insomnia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06736548 currently recruiting?
Yes, NCT06736548 is actively recruiting participants. Contact the research team at STEP@dfci.harvard.edu for enrollment information.
Where is the NCT06736548 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06736548 clinical trial?
NCT06736548 is sponsored by Dana-Farber Cancer Institute. The principal investigator is Christopher Recklitis, PhD, MPH at Dana-Farber Cancer Institute. The trial plans to enroll 100 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.